Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

S116836

 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzamidesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm primarily due to the presence of the BCR-ABL fusion gene that… Expand
2018
2018
Abstract 1980: S116836 overcomes BCR-ABL T315I mutation mediated imatinib resistance in chronic myeloid leukemia
Chronic Myeloid Leukemia (CML) is largely caused by the Philadelphia (Ph) chromosome carrying the Break point Cluster Region… Expand
2014
2014
SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells
Limited treatment options are available for chronic myelogenous leukemia (CML) patients who develop imatinib mesylate (IM… Expand
2014
2014
Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells
The FIP1-like-1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRα) fusion oncogene is the driver factor in a subset of… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2014
2014
70 Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRa-expressing cells
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE